Iteos Therapeutics Stock Alpha and Beta Analysis
| ITOS Stock | USD 8.19 0.05 0.61% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Iteos Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Iteos Therapeutics over a specified time horizon. Remember, high Iteos Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Iteos Therapeutics' market risk premium analysis include:
Beta 1.4 | Alpha (1.20) | Risk 4.46 | Sharpe Ratio (0.23) | Expected Return (1.03) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Iteos |
Iteos Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Iteos Therapeutics market risk premium is the additional return an investor will receive from holding Iteos Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Iteos Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Iteos Therapeutics' performance over market.| α | -1.2 | β | 1.40 |
Iteos Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Iteos Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Iteos Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Iteos Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Iteos Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Iteos Therapeutics shares will generate the highest return on investment. By understating and applying Iteos Therapeutics stock market price indicators, traders can identify Iteos Therapeutics position entry and exit signals to maximize returns.
Iteos Therapeutics Return and Market Media
The median price of Iteos Therapeutics for the period between Wed, Aug 28, 2024 and Tue, Nov 26, 2024 is 9.69 with a coefficient of variation of 28.58. The daily time series for the period is distributed with a sample standard deviation of 3.16, arithmetic mean of 11.04, and mean deviation of 2.59. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Ra Capital Management, L.p. of 5714285 shares of Iteos Therapeutics at 0.001 subject to Rule 16b-3 | 09/05/2024 |
2 | Disposition of 337109 shares by Davis Aaron I. of Iteos Therapeutics at 18.2487 subject to Rule 16b-3 | 09/06/2024 |
3 | HC Wainwright Reaffirms Buy Rating for iTeos Therapeutics | 09/16/2024 |
4 | Disposition of 1171 shares by Hallal David of Iteos Therapeutics at 19.51 subject to Rule 16b-3 | 09/25/2024 |
5 | TANG CAPITAL MANAGEMENT LLC Acquires New Stake in ITeos Therapeu - GuruFocus.com | 09/30/2024 |
6 | Acquisition by Lager Joanne Jenkins of 130000 shares of Iteos Therapeutics at 16.66 subject to Rule 16b-3 | 10/11/2024 |
7 | Acquisition by Iannone Robert of 17538 shares of Iteos Therapeutics subject to Rule 16b-3 | 10/22/2024 |
8 | iTeos Therapeutics prsentera les donnes prcliniques et translationnelles portant sur linupadnant, ainsi que les rsultats de lessai clinique de Phase2 A2A-005 po... | 10/25/2024 |
9 | Acquisition by Lee David K of 44766 shares of Iteos Therapeutics at 9.84 subject to Rule 16b-3 | 11/01/2024 |
10 | iTeos verkndet Finanzergebnisse fr das dritte Quartal 2024 und gibt aktuelle Geschftsinformationen bekannt | 11/13/2024 |
11 | iTeos Therapeutics, Inc. Third-Quarter Results Heres What Analysts Are Forecasting For Next Year | 11/15/2024 |
12 | Acquisition by Matthew Gall of 5000 shares of Iteos Therapeutics at 7.727 subject to Rule 16b-3 | 11/19/2024 |
13 | Insider Buying Matthew Gall Acquires 5,000 Shares of ITeos Therapeutics Inc | 11/20/2024 |
14 | BIOTECHNOLOGY VALUE FUND L P Increases Stake in ITeos Therapeutics Inc | 11/22/2024 |
About Iteos Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Iteos or other stocks. Alpha measures the amount that position in Iteos Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 3.32 | 188.37 | 197.79 | PTB Ratio | 1.05 | 0.68 | 0.65 |
Iteos Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Iteos Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Iteos Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Iteos Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Iteos Therapeutics. Please utilize our Beneish M Score to check the likelihood of Iteos Therapeutics' management manipulating its earnings.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Iteos Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.